Recruitment of subjects in industry-sponsored multicenter international clinical trials

被引:0
|
作者
Batagello, Rodrigo [1 ]
机构
[1] Pontificia Univ Catolica Parana, Programa Posgrad Bioet, Curitiba, Parana, Brazil
来源
SAUDE E SOCIEDADE | 2018年 / 27卷 / 04期
关键词
Patient Selection; Clinical Trial; Multicenter Study; International Cooperation; Research Subjects;
D O I
10.1590/S0104-12902018180292
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This study concerns the recruitment of research subjects in industry-sponsored multicentric international clinical trials carried out at a Brazilian public university between January 2010 and December 2016. A set of 63 clinical trial agreements, administrative and regulatory documents was analyzed. The results showed that 75 countries were involved in these international trials, of which 16% were Latin American. Data about the recruitment of research subjects at the local (356 subjects), national (3774 subjects) and international (82,696 subjects) levels were obtained, as well as information on the number of Brazilian research centers involved and the costs of each trial. Phase III trials were the most frequent (77.78% of the cases) and they estimated a total national enrollment between 18 and 80 research subjects per trial (which means between 4.42% and 11.46% of international recruitment). A negative correlation was found between agreements, research resources, recruitment data, and yearly average dollar exchange rate. All the trials adopted competitive recruitment method associated with payment for subject included in the research. This is worrying and shows contradiction between this practice and the recommended national ethical guidelines. The lack of data on recruitment at the national level reveals, in 19% of the cases, a frequent regulatory process failure. It is concluded that the availability of detailed data on recruitment for researches involving human beings is important for the accurate sizing and organization of the efforts to protect research subjects, and that currently this premise is not being appropriately followed.
引用
收藏
页码:1033 / 1043
页数:11
相关论文
共 50 条
  • [1] Industry-sponsored clinical trials: time to publication
    Mathias, Marla
    LaFlamme, K. Elizabeth
    Johnson, Tracy H.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 : S12 - S12
  • [2] Budget negotiation for industry-sponsored clinical trials
    Beal, K
    Dean, J
    Chen, J
    Dragaon, E
    Saulino, A
    Collard, CD
    [J]. ANESTHESIA AND ANALGESIA, 2004, 99 (01): : 173 - 176
  • [3] Industry-sponsored clinical trials and medical publishing
    N. J. C. Snell
    [J]. International Journal of Pharmaceutical Medicine, 2001, 15 (5) : 217 - 218
  • [4] Ethical considerations in industry-sponsored Multiregional Clinical Trials
    Ibia, Ekopimo
    Binkowitz, Bruce
    Saillot, Jean-Louis
    Talerico, Steven
    Koerner, Chin
    Ferreira, Irene
    Agarwal, Anupam
    Metz, Craig
    Maman, Marianne
    [J]. PHARMACEUTICAL STATISTICS, 2010, 9 (03) : 230 - 241
  • [5] Development of an authorship algorithm for industry-sponsored clinical trials
    Fusaro, Gina
    Matheis, Robert
    Weigel, Al
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 : S13 - S13
  • [6] Emergency medicine leadership in industry-sponsored clinical trials
    Newgard, CD
    Kim, S
    Camargo, CA
    [J]. ACADEMIC EMERGENCY MEDICINE, 2003, 10 (02) : 169 - 174
  • [7] Recent trends and controversies in industry-sponsored clinical trials
    Reed, CR
    Camargo, CA
    [J]. ACADEMIC EMERGENCY MEDICINE, 1999, 6 (08) : 833 - 839
  • [8] Mitigating Administrative Risks in Industry-sponsored Clinical Trials
    Kim, Paul J.
    [J]. JOURNAL OF FOOT & ANKLE SURGERY, 2011, 50 (06): : 633 - 634
  • [9] Medical journals, academia, and industry-sponsored clinical trials
    Frighi, V
    [J]. PLOS MEDICINE, 2005, 2 (07) : 686 - 686
  • [10] The potential for bias in reporting of industry-sponsored clinical trials
    Pyke, Stephen
    Julious, Steven A.
    Day, Simon
    O'Kelly, Michael
    Todd, Susan
    Matcham, James
    Seldrup, Jorgen
    [J]. PHARMACEUTICAL STATISTICS, 2011, 10 (01) : 74 - 79